https://www.fda.gov/drugs
https://www.fda.gov/drugs
Spark Therapeutics, Inc LUXTURNATM (voretigene neparvovec)
https://www.fda.gov/media/108385/download
glybera assessment report
https://www.ema.europa.eu/en/search/search?search_api_views_fulltext=glybera+assessment+report
Kymriah assessment report
https://www.ema.europa.eu/en/documents/assessment-report/kymriah-epar-public-assessment-report_en.pdf
Zolmoxis assessment report
https://www.ema.europa.eu/en/search/search?search_api_views_fulltext=Zolmoxis+assessment+report
Luxturna assessment report
https://www.ema.europa.eu/en/search/search?search_api_views_fulltext=Luxturna+assessment+report
Strimvelis assessment report
https://www.ema.europa.eu/en/documents/assessment-report/strimvelis-epar-public-assessment-report_en.pdf
reflection paper on design modifications of gene therapy medicinal products during development
https://www.ema.europa.eu/en/search/search?search_api_views_fulltext=reflection%20paper%20on%20design%20modifications%20of%20gene%20therapy%20medicinal
European Medicines Agency
https://www.ema.europa.eu/en/glossary/european-public-assessment-report
Implementing the Principles of Quality by
https://cdn.ymaws.com/www.casss.org/resource/resmgr/WCBP/2012_WCBP_KellyMichael.pdf
Design for Early Stage Gene Therapy Products
Implementing the Principles of Quality by
https://link.springer.com/article/10.1007%2Fs11095-018-2554-7
Design for Early Stage Gene Therapy Products
Hemophilia Gene Therapy: Ready for Prime Time?
https://www.researchgate.net/publication/319049156_Hemophilia_Gene_Therapy_Ready_for_Prime_Time
Development of Safer Gene Delivery Systems to Minimize the Risk of Insertional Mutagenesis-Related Malignancies: A Critical Issue for the Field of Gene Therapy
https://www.researchgate.net/publication/319049156_Hemophilia_Gene_Therapy_Ready_for_Prime_Time
Pharmacokinetic Study of Viral Vectors for Gene Therapy: Progress and Challenges
https://www.intechopen.com/books/viral-gene-therapy/pharmacokinetic-study-of-viral-vectors-for-gene-therapy-progress-and-challenges
Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy.
https://www.ncbi.nlm.nih.gov/pubmed/25607839
Rational Design of Gene Therapy Vectors
https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501(19)30012-9
Special delivery by tweaking a virus’s shell, Luk Vandenberghe thinks he can transpaort>>>
https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501(19)30012-9
関連記事:
[Data Link] GMP関連ガイドライン
[Link] 遺伝子治療のFDAガイダンス – ID8495 [2020/02/03]
[Bio-Edu] 治験実施までの留意事項 – 製薬協 – ID8497 [2020/02/03]
[Data Link] FDAの遺伝子治療薬への強いサポートの表明 – ID8513 [2020/01/28]
[用語] 希少疾患 [2021/10/16]
[用語] CTD : Common Technical Document
[医薬品] ウロキナーゼ [2020/06/29]
[用語] HSCT; 造血幹細胞移植 [2020/08/11]
[抗体医薬] アルツハイマー病治療薬: Biogen & エーザイ 共同開発 ADUHELM はアメリカでは条件付き承認，エーザイ& BioArctic AB共同開発のlecanemabは日本で承認取得[2023/10/11]
[用語] PDUFA [医療] [2022/09/03]